Association between severity of lower urinary tract symptoms, erectile dysfunction and metabolic syndrome

Aging Male

Volumn 12, Issue 1, 2009, Pages 29-34

  Demir, Omer ^a   Akgul, Korhan ^b   Akar, Zafer ^c   Cakmak, Ozgur ^d   Ozdemir, Ismail ^a   Bolukbasi, Ahmet ^d   Can, Ertan ^b   Gumus, Bilal H ^c  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Izmir Tepecik Training and Research Hospital   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

^d ATATURK TRAINING AND RESEARCH HOSPITAL   (Turkey)

Author keywords

Erectile dysfunction; Lower urinary tract symptoms; Metabolic syndrome

Indexed keywords

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; ERECTILE DYSFUNCTION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT DISEASE; WAIST CIRCUMFERENCE; BODY SIZE; COMORBIDITY; CROSS-SECTIONAL STUDY; MICTURITION DISORDER; MIDDLE AGED; OBESITY; RISK FACTOR;

BODY MASS INDEX; BODY SIZE; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; ERECTILE DYSFUNCTION; HUMANS; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PREVALENCE; QUALITY OF LIFE; RISK FACTORS; URINATION DISORDERS;

EID: 66149139875     PISSN: 13685538     EISSN: 14730790     Source Type: Journal    
DOI: 10.1080/13685530902777425     Document Type: Article

References (30)

1. Rosen R, Altwein J, Boyle P, Kirby RS, Lukacs B, Meuleman E, O'Leary MP, Puppo P, Robertson C, Giuliano F. Lower urinary tract symptoms and male sexual dysfunction: The multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
2. Vallancien G, Emberton M, Harving N, Van Moorselaar RJ; Alf-One Study Group. Sexual dysfunction in 1274 European men suffering from lower urinary tract symptoms. J Urol 2003; 169:2257-2261.
3. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of aging men from five Asian countries. BJU Int 2005;96:1339-1354.
4. Aslan G, Cavus E, Karas H, Oner O, Duran F, Esen A. Association between lower urinary tract symptoms and erectile dysfunction. Arch Androl 2006;52:155-162.
5. Demir O, Murat N, Aslan G, Gidener S, Esen A. Effect of doxazosin with and without rho-kinase inhibitor on human corpus cavernosum smooth muscle in the presence of bladder outlet obstruction. J Urol 2006;175:2345-2349.
6. Ellenberg M. Development of urinary bladder dysfunction in diabetes mellitus. Ann Int Med 1980;92:321-323.
7. Rohrmann S, Smit E, Giovanucci E, Platz EA. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obesity 2005; 29:310-316. (Pubitemid 40333230)
8. Ozden C, Ozdal LO, Urgancioglu G, Koyuncu H, Gokkaya S, Memis A. The correlation between metabolic syndrome and prostatic growth in patients with benign prostatic hyperplasia. Eur Urol 2007;51:199-206.
9. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486-2497.
10. Kasturi S, Russell S, McVary KT. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006;7:288-292. (Pubitemid 44623991)
11. Hammarsten J, Högstedt B, Holthuis N, Mellström D. Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 1998;1:157-162.
12. McVary K. Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 2005;47:838-845. (Pubitemid 40745354)
13. Berger AP, Bartsch G, Deibl M, Alber H, Pachinger O, Fritsche G, Rantner B, Fraedrich G, Pallwein L, Aigner F, Horninger W, Frauscher F. Atherosclerosis as a risk factor for benign prostatic hyperplasia. BJU Int 2006;98: 1038-1042.
14. McVary KT, Rademaker A, Lloyd GL, Gann P. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005;174:1327-1333.
15. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004;43:179-184.
16. Hammarsten J, Hogstedt B. Clinical, anthropometric, metabolic and insulin profile of men with fast annual growth rates of benign prostatic hyperplasia. Blood Press 1999;8:29-36.
17. Pradidarcheep W. Lower urinary tract symptoms and its potential relation with late-onset hypogonadism. Aging Male 2008;11:51-55.
18. Lee E, Park MS, Shin C, Lee H, Yoo K, Kim Y, Shin Y, Paik HY, Lee C. A high-risk group for prostatism: A populationbased epidemiological study in Korea. Br J Urol 1997;79:736-741.
19. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, James SA, Cooney KA, Doerr KM, Montie JE, Schottenfeld D. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003;157:906-914.
20. Field AE, Colditz GA, Willett WC, Longcope C, McKinlay JB. The relation of smoking, age, relative weight, and dietary intake to serum adrenal steroids, sex hormones, and sex hormone-binding globulin in middle-aged men. J Clin Endocrinol Metab 1994;79:1310-1316.
21. Haass M, Kubler W. Nicotine and sympathetic neurotransmission. Cardiovasc Drugs Ther 1997;10:657-665.
22. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S, Tsilidis KK, Smit E, Giovannucci E, Platz EA. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007;69:708-713. (Pubitemid 46574931)
23. Miwa Y, Kaneda T, Yokoyama O. Association between lower urinary tract symptoms and serum levels of sex hormones in men. Urology 2008;72:552-555.
24. Koritsiadis G, Stravodimos K, Mitropoulos D, Doumanis G, Fokitis I, Koritsiadis S, Constantinides C. Androgens and bladder outlet obstruction: A correlation with pressureflow variables in a preliminary study. BJU Int 2008;101: 1542-1546.
25. Laaksonen DE, Niskanen L, Punnonen K, Nyyssönen K, Tuomainen TP, Valkonen VP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036-1041.
26. Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000;85:2839-2853.
27. Bhasin S, Bagatell CJ, Bremner WJ, Plymate SR, Tenover JL, Korenman SG, Nieschlag E. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998;83:3435-3448.
28. Holmäng A, Björntorp P. The effects of testosterone on insulin sensitivity in male rats. Acta Physiol Scand 1992; 146:505-510.
29. Traish AM, Toselli P, Jeong SJ, Kim NN. Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: A potential mechanism for veno-occlusive dysfunction in androgen deficiency. J Androl 2005;26: 242-248.
30. Makhsida N, Shah J, Yan G, Fisch H, Shabsigh R. Hypogonadism and metabolic syndrome: Implications for testosterone therapy. J Urol 2005;174:827-834 (Pubitemid 41140604)